

**Amendments to the claims:**

This listing of claims will replace all prior versions and listing of claims in the application:

## Listing of Claims:

Claims 1-20 (canceled).

<sup>1</sup>  
Claim ~~21~~ (currently amended) A peptide or polypeptide or a fragment thereof comprising an Fv molecule, wherein said Fv molecule comprises a heavy chain variable region and a light chain variable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags, and wherein the heavy chain variable region comprises CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOs:8, 115 and 114, respectively[.]; and wherein the Fv molecule ~~wherein the peptide or polypeptide~~ is capable of binding one or more cell types selected from the group consisting of leukemia cells and cells expressing glycolalicin.

Claims 22-41 (canceled).

<sup>2</sup>  
Claim ~~42~~ (previously presented) The peptide or polypeptide of claim <sup>1</sup>~~21~~, wherein the heavy chain variable region comprises CDR3, CDR2 and CDR1 regions consisting of the amino acid sequences SEQ ID NOs:8, 115 and 114, respectively.

<sup>3</sup>  
Claim ~~43~~ (previously presented) The peptide or polypeptide of claim <sup>1</sup>~~21~~, wherein the CDR3 region consists of SEQ ID NO:8.

<sup>4</sup>  
Claim ~~44~~ (previously presented) The peptide or polypeptide of claim <sup>1</sup>~~21~~, wherein the CDR2 region consists of SEQ ID NO:115.

Claim ~~45~~<sup>5</sup> (previously presented) The peptide or polypeptide of claim ~~21~~<sup>1</sup>, wherein the CDR1 region consists of SEQ ID NO:114.

Claim 46 (cancelled).

Claim 47 (cancelled).

Claim ~~48~~<sup>6</sup> (currently amended) The peptide or polypeptide of claim ~~[[47]]~~<sup>1</sup>~~21~~ wherein the leukemia cells are selected from the group consisting of B lineage leukemia cells, T lineage leukemia cells, and myeloid lineage leukemia cells.

Claim ~~49~~<sup>7</sup> (previously presented) The peptide or polypeptide of claim ~~48~~<sup>6</sup> wherein the B lineage leukemia cells are selected from the group consisting of B-CLL and B-ALL.

Claim ~~50~~<sup>8</sup> (previously presented) The peptide or polypeptide of claim ~~48~~<sup>6</sup>, wherein the myeloid lineage leukemic cells are selected from the group consisting of CML and AML.

Claim ~~51~~<sup>9</sup> (currently amended) The peptide or polypeptide of claim ~~[[46]]~~<sup>1</sup>~~21~~ wherein the cells expressing glycolalicin are platelets.

Claim ~~52~~<sup>10</sup> (currently amended) The peptide or polypeptide of claim ~~42~~<sup>3</sup>, wherein the seFv has a light chain variable region consists ~~consisting~~ of SEQ ID NO:7.

Claim ~~53~~<sup>11</sup> (previously presented) ~~A~~<sup>A</sup> scFv consisting of SEQ ID NO:25.

Claim ~~54~~<sup>12</sup> (previously presented) ~~A~~<sup>A</sup> scFv consisting of SEQ ID NO:208.

Claim 56 (cancelled).